Read our Recent Headlines


Dec 04, 2019 by Dave Sobek

December 4th Biotech Update

The sector struggled a little and the momentum seems to have paused but we remain squarely within the uptrend. Of course, yesterday saw a ton of secondaries (the most I.

Share 0 Comments Read more
Dec 03, 2019 by Dave Sobek

December 3rd Biotech Update

The broader market backdrop is not nearly as positive with some China fears creeping into the market but the sector remains strong. I still think the stock reactions to ASH.

Dec 02, 2019 by Dave Sobek

December 2nd Biotech Update

The sector remains strong and we have ASH coming so we could see a run in some names this week. Given the recent strength and the potential run-up (uptrends are.

Nov 26, 2019 by Dave Sobek

November 26 Biotech Update

The trend is your friend and while I expected a news to slow we got an unanticipated surprise. Positive news continues to hit the sector and the trend continues higher..

Nov 25, 2019 by Dave Sobek

November 25th Biotech Update

If it were not for some M&A this would be a quiet start to the week. I suspect that in the end it will be pretty low on fundamental news.

Nov 20, 2019 by Dave Sobek

November 20th Biotech Update

The trend is our friend and it seems like the XBI wants to get to $90, although any price between now and then could see the pause. The worry would.

Nov 19, 2019 by Dave Sobek

November 19th Biotech Update

The leak is finally fixed. It only took six hours yesterday and an inadvertent flooding of the laundry room but it is done. Now I need to get the dry.

More From All Reports

Introduction


[videojs width="640" preload="auto" ogg="https://s3.amazonaws.com/chimeraresearchgroup.com/video/640ogg.ogg" webm="https://s3.amazonaws.com/chimeraresearchgroup.com/video/640webm.webm" mp4="https://s3.amazonaws.com/chimeraresearchgroup.com/video/640mp4.mp4"]

Overview

Chimera Research Group provides completely independent and actionable investment and trading ideas backed by comprehensive fundamental research and analysis for listed companies in the biotech and pharmaceutical sectors. Our coverage focuses on early stage companies with impending FDA decisions or clinical trial results but also includes mid-to-large cap bio-pharma companies where there exists specific catalysts. Our Trade Ideas are designed to maximize the risk reward profile. Our Research Reports outline the top up-and-coming catalysts that represent the best opportunities for traders and investors.


The biopharmaceutical sector offers significant opportunities to generate big returns yet can be risky and difficult to navigate. Subscribe to Chimera Research Group and proceed with confidence.

Get Started!


      Join      

 Learn More